SOLICITATION NOTICE
99 -- Neuropathology Service
- Notice Date
- 8/19/2010
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, NCTR-50 RM422 HFT-320, Jefferson, Arkansas, 72079, United States
- ZIP Code
- 72079
- Solicitation Number
- 1076724
- Archive Date
- 9/23/2010
- Point of Contact
- Marcia O Park, Phone: (870) 543-7405
- E-Mail Address
-
marcia.park@fda.hhs.gov
(marcia.park@fda.hhs.gov)
- Small Business Set-Aside
- Total Small Business
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12., in conjunction with FAR Part 13.5, as applicable and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. The solicitation number is 1076724. This solicitation is issued as a Request for Quotation (RFQ). The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2005-43, dated 8/2/2010. The associated North American Industry Classification System (NAICS) code is 541711, Research and Development in Biotechnology with a small business size standard of 500 employees. The Food and Drug Administration (FDA) is soliciting for the following: 1.Neuro degeneration histology and silver stain protocol processing 2.Switzer Multibrain technology, embedded in register processing and sectioning, or its equivalent 3.–Amino Cupric Silver method staining and mounting 4.–Counter stain against Amino CuAg utilizing neutral red 5.Slides with cover slips numbered sequentially and placed in order in slide boxes 6.– Board certified toxicologic neuropathologist to generate a report of findings for approximately 6336 slides 7.Packaging and handling of slides prior to shipping to the National Center for Toxicological Research, Jefferson, AR 8.Shipping insurance The neuropathology organization performing the work, will receive up to 100 perfusion fixed brains in individual numbered bottles containing fixative solution in lots of varying sizes (6-24 brains per shipment) for processing. Multiple brains will be embedded in register in the same block to allow each brain to be sliced at the same or comparable level. Each entire brain will be freeze sectioned at intervals of 40 microns in the plan designated (coronal). Every 8th section of each brain will be stained to generate 66 slides that represent the entire brain (this spans a length of 21 mm). Every eighth section which occurs at 320 um intervals will be stained by the Amino cupric Silver Method of deOlmos et.al. –Neurotox and Teratol 16:545-561 (1994) to reveal neurodegeneration. Each stained section will also be counterstained with Neutral Red to reveal cell bodies. Coverslips will be placed on each slide which will be labeled (numbered) and placed in serial order in slide boxes. Once the slides have been read by a Neuropathologist and reports have been generated these slides will be shipped to FDA – NCTR, Jefferson, AR In addition, unstained sections, adjacent to each stained section (e.g., section 7 and 9) will be identified and placed in cups containing antigen preserve solution. The other unstained sections will be placed together in a cup (containing antigen preserve solution) that is labeled to match the corresponding stained section and these cups (66) will also be shipped to the same above address at FDA. The performance of tasks necessary will include having these slides (66 per rat brain) be read and compared to MRI images by a highly qualified Board Certified Neuropathologist who will generate a report that describes 1) the findings for each slide examined; 2) an estimate of the accuracy of the MRI prediction of toxicity localization (e.g., how close was the MRI prediction of the locus of greatest toxicity to the actual section determined by the Neuropathologist to show the greatest toxicity in examination of all slides from a particular brain sample). The Neuropathologist shall also be available to discuss the findings of the report with study directors at FDA. Final Reports of the Neuropathologist shall be sent to FDA. An official authorized to bind the Offeror must sign the terms and conditions of the offer. Contract type: Commercial item – firm fixed price. The estimated period of performance is one year after receipt of order. Partial payments may be made upon generation of Neuropathologist report and shipment of slides to NCTR. Evaluation Criteria: The Government will award a contract resulting from this solicitation to the responsible offeror whose quote offers the best value to the Government, price and other factors considered. The following factors shall be used to evaluate offers: 1)Technical ability of offeror to meet or exceed the Government’s requirement, 2) past performance 3) price. Offers must furnish evidence of their capability to perform the scope of work by furnishing a technical proposal which outlines their technical approach to the scope of work and identify key personnel. Past performance information must include two recent or relevant contracts within the last two years and identify company name, point of contact name and telephone number for each contract. The Government reserves the right to make an award without discussion. Offerors must include a completed copy of the provision at FAR 52.212-3, Offeror Representations and Certifications – Commercial Items with its offer. Offerors that fail to complete the representations on the Online Representations and Certifications site (ORCA), or reject the terms and conditions of this solicitation, may be excluded from consideration for award. Offers must be submitted on a SF-1449, which can be found at http://www.gsa.gov/Portal/gsa/ep/formslibrary.do?formType+SF The clause at 52.212-4, Contract Terms and Conditions – Commercial Items, applies to this acquisition. The following addenda have been attached to the clause: None. The clause at FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders – Commercial Items, applies to this acquisition. The following additional FAR clauses cited in this clause incorporated by reference are applicable: 52.203-6, 52.219-4, 52.219-8, 52-.19-9, 52.222-3, 52.222-19, 52.222-21, 52.222-26,52.222-35, 52.222-36, 52.222-37. 52.222-39, 52.225-1, 52.225-13, and 52.232.33. Clauses and Provisions can be obtained at http://www.acquisition.gov CCR Requirement – Company must be registered in the Central Contractor Registration (CCR) before an award may be made to them. If a company is not registered in CCR, they may do so by going to the CCR web site at http://www.ccr.gov. A Duns and Bradstreet number is required to register with the CCR. The Defense Priorities and Allocations System (DPAS) and assigned rating are not applicable to this solicitation notice. Offers are due by postal mail to the attention of Marcia Park, Contract Specialist, FDA, NCTR, 3900 NCTR Road, HFT-323, Jefferson, AR 72079-9502; email to marcia.park@fda.hhs.gov or fax to 870/543-7990 on or before 1:00 PM, local prevailing time Jefferson, AR on September 8, 2010. For information regarding this RFQ, please contact Marcia Park at 870/543-7405 or by email at marcia.park@fda.hhs.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/NCTR/1076724/listing.html)
- Place of Performance
- Address: FDA/National Center for Toxicological Research, 3900 NCTR Road, Jefferson, Arkansas, 72079, United States
- Zip Code: 72079
- Zip Code: 72079
- Record
- SN02247113-W 20100821/100819235630-aa384a624f5e658187da1d5af542c0f4 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |